Outline: Non-Exhaustive Sampling > US Government Grants.
For: 'Hantavirus' related research.
From: US National Institute of Health / US National Institute of Allergy & Infectious Disease.
1. 2021 Grant: "Viral and host determinants of susceptibility of diverse hantaviruses".
* Award Number: 5R21AI156482-03.
* Institution: Rohit K. Jangra (Assistant Professor), Louisiana State University Health Sciences Center Shreveport.
* Period: June 1, 2021 – May 31, 2025
* 2022 funding: $186,390.
* Summary: Develop tools (e.g., recombinant vesicular stomatitis viruses displaying hantavirus glycoproteins) to study virus entry and replication for >40 genetically diverse hantaviruses.
2. 2017 Grant: "A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome".
* Award Number: 5R42AI132047-05.
* Institution: Joana M. Murad (Celdara Medical, LLC, Lebanon, NH), in collaboration with Jason Botten (University of Vermont).
* Period: August 8, 2017 – February 28, 2026
* 2025 funding: $955,865.
* Summary: Develop potent human neutralizing monoclonal antibodies (isolated from patients) as a first-line antiviral for HCPS caused by Andes virus (ANDV) and related hantaviruses like Sin Nombre virus (SNV). Address person-to-person transmission risk and bioterrorism potential.
3. 2020 Grant: "Mechanisms of Intrinsic Host Responses to Hantavirus Infection".
* Award Number: 5K22AI141680-02.
* Institution: Alison Kell (Assistant Professor), University of New Mexico Health Sciences Center.
* Period: February 14, 2020 – April 30, 2022.
* 2021 funding: $106,320.
* Summary: Examines innate antiviral signaling (e.g., MAVS/type I interferon) and virus-host interactions in human endothelial cells vs. rodent reservoirs for Old World hantaviruses like Hantaan (HTNV) and Seoul (SEOV) viruses.
4. 2017 Grant: "Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome".
* Award Number: 3R41AI132047-01S1.
* Institution: Jason W. Botten (Celdara Medical, LLC, in collaboration with University of Vermont).
* Period: 2017 onward.
* 2018 funding: $54,079.
* Summary: Fund development of human neutralizing monoclonal antibodies isolated from survivors as a first-line therapeutic/prophylactic for hantavirus cardiopulmonary syndrome (HCPS) caused by Andes virus (ANDV) and related strains like Sin Nombre virus (SNV). Address ~40% fatality, rodent reservoirs, and rare person-to-person transmission.
5. 2019 Grant: "Prometheus Center for Excellence in Translational Research; multi-project center grant".
* Total Award (umbrella'd across several individualized grant numbers): $22 million over 5 years.
* Institution: Albert Einstein College of Medicine (Kartik Chandran, Ph. D., lead), with international consortium partners including U. S. Army Medical Research Institute of Infectious Diseases
* Period: 2019 onward.
* Summary: Large-scale translational effort to develop monoclonal antibody-based therapies against Andes virus (ANDV), Sin Nombre virus (SNV), Puumala virus (PUUV), and Crimean-Congo hemorrhagic fever virus (CCHFV). Focused on Category A priority pathogens with high lethality and biodefense potential. Funded antibody discovery, preclinical testing, and advancement toward clinical use. Direct multi-million-dollar NIAID transfer to Einstein and collaborators for collaborative, high-impact countermeasure development. Related investigator grants (e.g., R01 AI132633) support foundational hantavirus entry/glycoprotein work by same lab.
